Literature DB >> 728877

Metabolic epidemiology of large bowel cancer: fecal bulk and constituents of high-risk North American and low-risk Finnish population.

B S Reddy, A R Hedges, K Laakso, E L Wynder.   

Abstract

The dietary pattern and fecal constituents of two populations with distinct risk for the development of colon cancer, a high-risk population in New York Metropolitan area and a low-risk population in rural Kuopio, were studied. The average daily intake of dietary fat and protein was the same in the two groups, but the sources of fat were different, a greater portion coming from dairy products in rural Kuopio and from meat in the New York Metropolitan area. Not only the frequency of bowel movements was higher, but also the daily total stool output as well as the fecal fiber excretion were greater in Kuopio compared with New York due to high dietary intake in rural Kuopio of cereal products rich in fiber. The concentration of fecal secondary bile acids and bacterial beta-glucuronidase activity was lower in rural Kuopio, but the total daily excretion of these constituents was the same in two populations. The daily fecal excretion of bacterial nuclear dehydrogenase activity and of neutral sterols was higher in rural Kuopio, and the concentration of these constituents was the same in the two groups. The high daily excretion of cholesterol metabolites in Kuopio might be due to high dietary intake of dairy products. The data suggest that one of the factors contributing to the low-risk of large bowel cancer in Finland, in spite of high dietary intake of fat, appears to be the fact that a high dietary fiber leads to an increase in stool bulk, thus diluting bile acids, which have promoting activity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 728877     DOI: 10.1002/1097-0142(197812)42:6<2832::aid-cncr2820420644>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

1.  Nutrition: the need to define "optimal" intake as a basis for public policy decisions.

Authors:  E L Wynder; J H Weisburger; S K Ng
Journal:  Am J Public Health       Date:  1992-03       Impact factor: 9.308

2.  Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.

Authors:  Zhongsheng Peng; Jiayan Chen; Cinthia B Drachenberg; Jean-Pierre Raufman; Guofeng Xie
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

Review 3.  Diet, the gut microbiome, and epigenetics.

Authors:  Meredith A J Hullar; Benjamin C Fu
Journal:  Cancer J       Date:  2014 May-Jun       Impact factor: 3.360

Review 4.  Fiber and cancer.

Authors:  D Kritchevsky
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

5.  Nondegradation of fecal cholesterol in subjects at high risk for cancer of the large intestine.

Authors:  M Lipkin; B S Reddy; J Weisburger; L Schechter
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

Review 6.  Colorectal carcinomas: diagnostic implications of their changing frequency and anatomic distribution.

Authors:  G G Ghahremani; K Dowlatshahi
Journal:  World J Surg       Date:  1989 May-Jun       Impact factor: 3.352

7.  Fat intake and cancer of the gastrointestinal tract and prostate.

Authors:  R MacLennan
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

8.  Influence of age, intestinal transit time, and dietary composition on fecal bile acid profiles in healthy subjects.

Authors:  F M Nagengast; S D van der Werf; H L Lamers; M P Hectors; W C Buys; J M van Tongeren
Journal:  Dig Dis Sci       Date:  1988-06       Impact factor: 3.199

9.  Effects of bile acids on the mutagenicity and recombinogenicity of triethylene melamine in yeast strains MP1 and D61.M.

Authors:  R Fahrig
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

Review 10.  Dietary fibre and colon cancer: epidemiologic and experimental evidence.

Authors:  B S Reddy
Journal:  Can Med Assoc J       Date:  1980-11-08       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.